Prelude Therapeutics Investor Relations Material
Latest events
Study Update
Prelude Therapeutics
Q2 2025
14 Aug, 2025
Q1 2025
6 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Prelude Therapeutics Inc
Access all reports
Prelude Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, small molecule therapies targeting key drivers of cancer cell growth and resistance. Leveraging its expertise in cancer biology, medicinal chemistry, and drug development, Prelude Therapeutics is committed to advancing a pipeline of innovative treatments aimed at addressing the complex challenges of cancer treatment. The company is headquartered in Wilmington, Delaware, and its shares are listed on the Nasdaq.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
PRLD
Country
🇺🇸 United States